Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
You may also be interested in...
Pfizer And Moderna Reap Rewards Of Expanded US And EU Deals
The two rival mRNA vaccines are proving attractive in the face of new variants, and could dominate once SARS-CoV2 enters the ‘endemic’ stage.
Predicting Success: The Easiest, And Hardest Routes To Market
A new analysis from BIO, Informa Pharma Intelligence and QLS looks at clinical drug development activity from the past decade, looking at the most (and least) successful areas. Infographic depicts key trends and details.
Bluebird Sickle Cell Gene Therapy Hangs In Balance
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”